Suzetrigine has generated understandable enthusiasm as a first-in-class, non-opioid analgesic targeting peripheral Nav1.8 sodium channels. For perioperative clinicians seeking alternatives to opioid-centered pain management, this mechanism is attractive. Yet two distinct challenges must be
Khan et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: